HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
FYN
FYN proto-oncogene, Src family tyrosine kinase
Chromosome 6 · 6q21
NCBI Gene: 2534Ensembl: ENSG00000010810.19HGNC: HGNC:4037UniProt: P06241
667PubMed Papers
20Diseases
6Drugs
3Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub GeneKinaseOncogene
RESEARCH IMPACT
Highly Studied
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
growth factor receptor bindingscaffold protein bindingdisordered domain specific bindingnon-membrane spanning protein tyrosine kinase activitychronic myelogenous leukemiacanceracute lymphoblastic leukemianeurodegenerative disease
✦AI Summary

FYN is a non-receptor tyrosine kinase of the Src family that phosphorylates diverse cellular substrates to regulate multiple biological processes. FYN functions in cell adhesion and motility by phosphorylating adhesion molecules including β-catenin and δ-catenin 1, and regulates cytoskeletal remodeling through phosphorylation of actin regulators and microtubule-associated proteins 23. In immune signaling, FYN participates in T-cell receptor (TCR) signaling by phosphorylating downstream effectors including DAB1 in reelin signaling and regulating both positive and negative feedback loops through phosphorylation of PAG1 and PDCD1 45. FYN also modulates natural killer cell activation through CD244 signaling 6. Beyond immune function, FYN regulates glomerular slit diaphragm integrity by phosphorylating components including NPHS1 and TRPC6 78, and promotes neuronal processes by phosphorylating neural proteins such as DPYSL2 and SNCA 910. Dysregulation of FYN is implicated in multiple pathologies: elevated FYN expression promotes proliferation and metastasis in gastric cancer through TOPK phosphorylation 11, FYN polymorphisms associate with increased thyroid cancer risk 12, and FYN acts as a risk factor in Parkinson's disease through microglial Kv1.3 channel modulation 13. Additionally, elevated FYN transcription drives autoimmunity and Th2 polarization in IgG4-related disease 14, highlighting FYN's importance as both a therapeutic target and prognostic marker across diverse diseases.

Sources cited
1
FYN functions in cell adhesion and motility by phosphorylating adhesion molecules including β-catenin and δ-catenin , and regulates cytoskeletal remodeling through phosphorylation of actin regulators and microtubule-associated proteins , .
PMID: 17194753
2
FYN also modulates natural killer cell activation through CD244 signaling .
PMID: 15713798
3
Dysregulation of FYN is implicated in multiple pathologies: elevated FYN expression promotes proliferation and metastasis in gastric cancer through TOPK phosphorylation , FYN polymorphisms associate with increased thyroid cancer risk , and FYN acts as a risk factor in Parkinson's disease through microglial Kv1.3 channel modulation .
PMID: 37016377
4
Dysregulation of FYN is implicated in multiple pathologies: elevated FYN expression promotes proliferation and metastasis in gastric cancer through TOPK phosphorylation , FYN polymorphisms associate with increased thyroid cancer risk , and FYN acts as a risk factor in Parkinson's disease through microglial Kv1.3 channel modulation .
PMID: 36058999
5
Dysregulation of FYN is implicated in multiple pathologies: elevated FYN expression promotes proliferation and metastasis in gastric cancer through TOPK phosphorylation , FYN polymorphisms associate with increased thyroid cancer risk , and FYN acts as a risk factor in Parkinson's disease through microglial Kv1.3 channel modulation .
PMID: 32597830
6
Additionally, elevated FYN transcription drives autoimmunity and Th2 polarization in IgG4-related disease , highlighting FYN's importance as both a therapeutic target and prognostic marker across diverse diseases.
PMID: 38885295
Disease Associationsⓘ20
chronic myelogenous leukemiaOpen Targets
0.60Moderate
cancerOpen Targets
0.59Moderate
acute lymphoblastic leukemiaOpen Targets
0.53Moderate
neurodegenerative diseaseOpen Targets
0.53Moderate
ebv-positive nodal t- and nk-cell lymphomaOpen Targets
0.50Moderate
Parkinson diseaseOpen Targets
0.48Moderate
hypothyroidismOpen Targets
0.47Moderate
cutaneous LeishmaniasisOpen Targets
0.46Moderate
neoplasmOpen Targets
0.43Moderate
lymphoid leukemiaOpen Targets
0.39Weak
HIV infectionOpen Targets
0.39Weak
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveOpen Targets
0.39Weak
myxedemaOpen Targets
0.37Weak
DNA methylationOpen Targets
0.34Weak
autoimmune thyroid diseaseOpen Targets
0.32Weak
schizophreniaOpen Targets
0.32Weak
thyroid diseaseOpen Targets
0.31Weak
autoimmune diseaseOpen Targets
0.31Weak
acute myeloid leukemiaOpen Targets
0.30Weak
leukemiaOpen Targets
0.30Weak
Pathogenic Variants3
NM_002037.5(FYN):c.286C>G (p.Arg96Gly)Pathogenic
EBV-positive nodal T- and NK-cell lymphoma
☆☆☆☆→ Residue 96
NM_002037.5(FYN):c.286C>T (p.Arg96Trp)Pathogenic
EBV-positive nodal T- and NK-cell lymphoma
☆☆☆☆→ Residue 96
NM_002037.5(FYN):c.289A>G (p.Thr97Ala)Pathogenic
EBV-positive nodal T- and NK-cell lymphoma
☆☆☆☆→ Residue 97
View on ClinVar ↗
Drug Targets6
DASATINIB ANHYDROUSApproved
Bcr/Abl fusion protein inhibitor
acute lymphoblastic leukemia
ENMD-981693Phase II
Fibroblast growth factor receptor inhibitor
ILORASERTIBPhase II
Platelet-derived growth factor receptor inhibitor
JNJ-26483327Phase I
Receptor protein-tyrosine kinase erbB-4 inhibitor
TG100-801Phase II
Ephrin type-B receptor 4 inhibitor
macular degeneration
XL-228Phase I
Insulin-like growth factor I receptor inhibitor
childhood leukemia
Related Genes
GRB2Protein interaction100%NCK1Protein interaction100%PIK3CBProtein interaction100%PIK3CAProtein interaction100%GRIN2BProtein interaction100%SH2D1AProtein interaction100%
Tissue Expression6 tissues
Brain
100%
Lung
45%
Bone Marrow
33%
Heart
32%
Ovary
23%
Liver
16%
Gene Interaction Network
Click a node to explore
FYNGRB2NCK1PIK3CBPIK3CAGRIN2BSH2D1A
PROTEIN STRUCTURE
Preparing viewer…
PDB7A2P · 0.90 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.21Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.11 [0.06–0.21]
RankingsWhere FYN stands among ~20K protein-coding genes
  • #329of 20,598
    Most Researched667 · top 5%
  • #730of 1,025
    FDA-Approved Drug Targets1
  • #3,891of 5,498
    Most Pathogenic Variants3
  • #535of 17,882
    Most Constrained (LOEUF)0.21 · top 5%
Genes detectedFYN
Sources retrieved50 papers
Response time—
📄 Sources
50▼
1
Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease.
PMID: 32597830
J Clin Invest · 2020
1.00
2
Advances in the expression and function of Fyn in different human tumors.
PMID: 37093456
Clin Transl Oncol · 2023
0.90
3
Phytochemical regulation of Fyn and AMPK signaling circuitry.
PMID: 25951818
Arch Pharm Res · 2015
0.86
4
Fyn and TOM1L1 are recruited to clathrin-coated pits and regulate Akt signaling.
PMID: 35238864
J Cell Biol · 2022
0.84
5
Tau pathway-based gene analysis on PET identifies CLU and FYN in a Korean cohort.
PMID: 39625110
Alzheimers Dement · 2025
0.82